Cite
HARVARD Citation
Goess, C. et al. (2019). ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation. Modern rheumatology. 29 (3), pp. 510-522. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Goess, C. et al. (2019). ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation. Modern rheumatology. 29 (3), pp. 510-522. [Online].